Type 1 Diabetes Treatment Market - Global Market Share, Trends, Analysis and Forecast, 2023-2032
The global type 1 diabetes treatment market was estimated to be US$ 7.02 Billion in 2022 and is expected grow at a CAGR of 7.8% between 2023 to 2032.
Type 1 diabetes is a chronic autoimmune disease characterized by the destruction of insulin-producing beta cells in the pancreas. This leads to an absolute insulin deficiency and a dependence on exogenous insulin for survival.
People with type 1 diabetes must constantly monitor their blood glucose levels and administer insulin as necessary to regulate their glucose levels and avoid both short-term and long-term complications, including high or low blood glucose, diabetic ketoacidosis, neuropathy, retinopathy, nephropathy, and cardiovascular disease.
Market Drivers
Growing awareness about the benefits of early diabetes diagnosis and treatment is driving the market growth
The global type 1 diabetes market is driven by several factors, including the increasing prevalence of diabetes, growing awareness about diabetes and its management, advancements in insulin delivery devices, growing investment in R&D for diabetes treatment, the growth of the global obesity epidemic, and growing awareness about the benefits of early diabetes diagnosis and treatment.
The number of people diagnosed with diabetes has been rapidly increasing due to aging populations, increasing obesity rates, and a growing adoption of sedentary lifestyles and unhealthy diets. There is a growing recognition of the importance of diabetes management and control, as well as the need for early diagnosis and treatment, fueling the demand for diabetes management products and services.
Significant advancements in insulin delivery devices, such as insulin pumps and pen injectors, have improved the quality of life for people with diabetes and made it easier for them to manage their condition. There has been a growing investment in R&D in the field of diabetes treatment, aimed at developing new and improved insulin delivery devices and continuous glucose monitoring systems.
The global obesity epidemic has been growing at an alarming rate, and obesity is a major risk factor for the development of type 2 diabetes. Finally, there is a growing awareness about the benefits of early diabetes diagnosis and treatment, including reducing the risk of long-term complications and improving quality of life.
Product type segmentation of Global Type 1 Diabetes Treatment Market
Increasing investment in R&D for diabetes treatment is driving the growth of the glucose monitoring systems segment
Based on product type the market is segmented into insulin products, insulin delivery devices, glucose monitoring systems, and other products.
Among these the insulin delivery devices segment is the largest segment in the type 1 diabetes market, based on product type. This is due to the growing adoption of insulin pumps and pen injectors, which have improved the quality of life for people with diabetes and made it easier for them to manage their condition.
The segment has seen significant advancements in recent years, including the development of more discreet and user-friendly devices, as well as improved accuracy and reliability.
The glucose monitoring systems segment is the fastest growing segment in the type 1 diabetes market. This is due to the increasing demand for continuous glucose monitoring (CGM) systems, which have improved the accuracy and reliability of glucose monitoring and have become a standard of care for people with type 1 diabetes.
The segment has seen the introduction of smart CGMs that can communicate with insulin pumps, allowing for real-time glucose monitoring and insulin delivery. The growing awareness about the benefits of early diabetes diagnosis and treatment and the increasing investment in R&D for diabetes treatment are also driving the growth of this segment.
End-user segmentation of Global Type 1 Diabetes Treatment Market
Home care is the largest end-user segment of the market
Based on end-user, the market is segmented into Hospital, Clinics, Research Institutes, and Home Care. The largest end-user segment in the type 1 diabetes market is home care, primarily due to the increasing trend of home-based diabetes management. With advancements in insulin delivery devices and continuous glucose monitoring systems, people with diabetes can now effectively manage their condition from the comfort of their own homes.
Home care provides people with diabetes with greater flexibility and control over their insulin therapy, allowing them to maintain consistent blood glucose levels and lead a more active and healthy lifestyle. Additionally, home-based diabetes management is often more cost-effective compared to hospital- or clinic-based management, making it a more attractive option for many people with diabetes.
The hospital and clinics segment is also significant, as many people with diabetes still require in-person visits with healthcare professionals for monitoring, insulin therapy adjustments, and to receive education and support. Research institutes also play a key role in the type 1 diabetes market, as they are involved in conducting research and developing new and improved treatments and products for diabetes management.
Regional trends of the Global Type 1 Diabetes Treatment Market
Increasing access to diabetes management products is fueling market growth in the Asia-Pacific
Geographically, the global type 1 diabetes treatment market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America.
Among these, the largest region in the global type 1 diabetes treatment market is North America, primarily due to the high prevalence of diabetes and the presence of a large number of leading diabetes treatment and management companies in the region. The North American market is characterized by strong healthcare infrastructure, a high standard of living, and a large patient pool, making it an attractive market for companies operating in the type 1 diabetes treatment space.
The fastest-growing region in the global type 1 diabetes treatment market is Asia-Pacific, primarily due to the rapidly increasing prevalence of diabetes in the region and the growing awareness about diabetes and its management.
The Asia-Pacific region is characterized by a large population, increasing urbanization, and a growing middle class, leading to an increase in the prevalence of obesity and sedentary lifestyles, which are major risk factors for the development of type 2 diabetes.
Additionally, the governments in the Asia-Pacific region are taking steps to increase awareness about diabetes and its management, as well as investing in the development of healthcare infrastructure and increasing access to diabetes management products and services, further fueling market growth in the region.
Key players and market strategies:
Companies operating in the type 1 diabetes market are adopting several growth strategies to increase their market share and stay ahead of their competitors. One of the key strategies is partnerships and collaborations with other companies, universities, and research institutions. These partnerships and collaborations allow companies to share resources, knowledge, and expertise, and to develop new and improved products and treatments for type 1 diabetes.
Another key strategy is research and development (R&D) investments. Companies are investing in R&D to develop new and improved treatments and products for type 1 diabetes, including insulin delivery devices, continuous glucose monitoring systems, and glucose sensors. Additionally, companies are investing in R&D to develop new and improved insulin formulations that are more effective, convenient, and easier to use.
Another strategy is the expansion of product portfolios through acquisitions and mergers. Companies are acquiring or merging with other companies to increase their product portfolios, expand their customer base, and enter new markets. Additionally, companies are focusing on expanding their market presence through the introduction of new products and the expansion of distribution networks.
Some of the biggest companies operating in the global type 1 diabetes treatment market are Abbott Laboratories (USA), Sanofi (France), Bayer AG (Germany), Becton, Dickinson and Company (USA), Dexcom, Inc. (USA), Eli Lilly and Company (USA), GlaxoSmithKline (UK), Insulet Corporation (USA), Medtronic plc (Ireland), Novo Nordisk A/S (Denmark), Roche Diabetes Care (Switzerland), Tandem Diabetes Care, Inc. (USA), Ypsomed Holding AG (Switzerland), and many more.
Global Type 1 Diabetes Treatment Market Segmentation:
By Product Type
- Insulin products
- rapid-acting insulin
- long-acting insulin
- pre-mixed insulin
- Insulin delivery devices
- Insulin pens
- Insulin pumps
- Insulin syringes
- Glucose monitoring systems
- Continuous glucose monitoring systems
- Self-monitoring blood glucose systems
- Other products
By End-User
- Hospital
- Clinics
- Research Institutes
- Home Care
By Region
- North America
- United States
- Canada
- Rest of North America
- Europe
- Germany
- United Kingdom
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- India
- China
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
- South America
- Brazil
- Rest of South America
- Introduction
- Research Objectives
- Report Assumptions
- Research Methodology
- Abbreviations
- Preface
- Market Definition
- Report Scope and Market Segmentation
- Research Highlights
- Market Synopsis: Global Type 1 Diabetes Treatment Market
- Global Type 1 Diabetes Treatment Market Qualitative Analysis
- Trends
- Market trends
- Technology Trends
- PESTLE Analysis (For 3 prominent countries)
- Market Influencers
- Driving Forces
- Hindering Forces
- Opportunities
- COVID-19 impact
- Porter’s Five Forces Analysis
- Value Chain Analysis
- Trends
- Global Type 1 Diabetes Treatment Market Analysis and Forecast, by Product Type
- Overview and definitions
- Key segment analysis
- Global Type 1 Diabetes Treatment Market Estimates (US$ Mn), Product Type, 2019 – 2032
- Insulin products
- Rapid-acting insulin
- Long-acting insulin
- Pre-mixed insulin
- Insulin delivery devices
- Insulin pens
- Insulin pumps
- Insulin syringes
- Glucose monitoring systems
- Continuous glucose monitoring systems
- Self-monitoring blood glucose systems
- Other products
- Insulin products
- Global Type 1 Diabetes Treatment Market Analysis and Forecast, by End Use
- Overview and definitions
- Key segment analysis
- Global Type 1 Diabetes Treatment Market Estimates (US$ Mn), by End Use, 2019 – 2032
- Hospital
- Clinics
- Research Institutes
- Home Care
- Global Type 1 Diabetes Treatment Market Analysis and Forecast, by Region
- Overview and definitions
- Key segment analysis
- Global Type 1 Diabetes Treatment Market Estimates (US$ Mn), by Region, 2019 – 2032
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- South America
- North America Type 1 Diabetes Treatment Market Analysis and Forecast
- Overview and definitions
- Key segment analysis
- North America Type 1 Diabetes Treatment Market Estimates (US$ Mn), Product Type, 2019 – 2032
- Insulin products
- Rapid-acting insulin
- Long-acting insulin
- Pre-mixed insulin
- Insulin delivery devices
- Insulin pens
- Insulin pumps
- Insulin syringes
- Glucose monitoring systems
- Continuous glucose monitoring systems
- Self-monitoring blood glucose systems
- Other products
- Insulin products
- North America Type 1 Diabetes Treatment Market Estimates (US$ Mn), by End Use, 2019 – 2032
- Hospital
- Clinics
- Research Institutes
- Home Care
- North America Type 1 Diabetes Treatment Market Estimates (US$ Mn), by Country, 2019 – 2032
- United States
- Canada
- Rest of North America
- Europe Type 1 Diabetes Treatment Market Analysis and Forecast
- Overview and definitions
- Key segment analysis
- Europe Type 1 Diabetes Treatment Market Estimates (US$ Mn), Product Type, 2019 – 2032
- Insulin products
- Rapid-acting insulin
- Long-acting insulin
- Pre-mixed insulin
- Insulin delivery devices
- Insulin pens
- Insulin pumps
- Insulin syringes
- Glucose monitoring systems
- Continuous glucose monitoring systems
- Self-monitoring blood glucose systems
- Other products
- Insulin products
- Europe Type 1 Diabetes Treatment Market Estimates (US$ Mn), by End Use, 2019 – 2032
- Hospital
- Clinics
- Research Institutes
- Home Care
- Europe Type 1 Diabetes Treatment Market Estimates (US$ Mn), by Country, 2019 – 2032
- Germany
- United Kingdom
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific Type 1 Diabetes Treatment Market Analysis and Forecast
- Overview and definitions
- Key segment analysis
- Asia Pacific Type 1 Diabetes Treatment Market Estimates (US$ Mn), Product Type, 2019 – 2032
- Insulin products
- Rapid-acting insulin
- Long-acting insulin
- Pre-mixed insulin
- Insulin delivery devices
- Insulin pens
- Insulin pumps
- Insulin syringes
- Glucose monitoring systems
- Continuous glucose monitoring systems
- Self-monitoring blood glucose systems
- Other products
- Insulin products
- Asia Pacific Type 1 Diabetes Treatment Market Estimates (US$ Mn), by End Use, 2019 – 2032
- Hospital
- Clinics
- Research Institutes
- Home Care
- Asia Pacific Type 1 Diabetes Treatment Market Estimates (US$ Mn), by Country, 2019 – 2032
- China
- Japan
- South Korea
- India
- Australia
- Rest of Asia Pacific
- Middle East & Africa Type 1 Diabetes Treatment Market Analysis and Forecast
- Overview and definitions
- Key segment analysis
- Middle East & Africa Type 1 Diabetes Treatment Market Estimates (US$ Mn), Product Type, 2019 – 2032
- Insulin products
- Rapid-acting insulin
- Long-acting insulin
- Pre-mixed insulin
- Insulin delivery devices
- Insulin pens
- Insulin pumps
- Insulin syringes
- Glucose monitoring systems
- Continuous glucose monitoring systems
- Self-monitoring blood glucose systems
- Other products
- Insulin products
- Middle East & Africa Type 1 Diabetes Treatment Market Estimates (US$ Mn), by End Use, 2019 – 2032
- Hospital
- Clinics
- Research Institutes
- Home Care
- Middle East & Africa Type 1 Diabetes Treatment Market Estimates (US$ Mn), by Country, 2019 – 2032
- UAE
- Saudi Arabia
- South Africa
- Rest of MEA
- South America Type 1 Diabetes Treatment Market Analysis and Forecast
- Overview and definitions
- Key segment analysis
- South America Type 1 Diabetes Treatment Market Estimates (US$ Mn), Product Type, 2019 – 2032
- Insulin products
- Rapid-acting insulin
- Long-acting insulin
- Pre-mixed insulin
- Insulin delivery devices
- Insulin pens
- Insulin pumps
- Insulin syringes
- Glucose monitoring systems
- Continuous glucose monitoring systems
- Self-monitoring blood glucose systems
- Other products
- Insulin products
- South America Type 1 Diabetes Treatment Market Estimates (US$ Mn), by End Use, 2019 – 2032
- Hospital
- Clinics
- Research Institutes
- Home Care
- South America Type 1 Diabetes Treatment Market Estimates (US$ Mn), by Country, 2019 – 2032
- Brazil
- Argentina
- Rest of South America
- Competition Analysis – Global Type 1 Diabetes Treatment Market
- Market Composition
- Market Share Analysis (%), by Supplier (2022)
- Company Profiles
- Abbott Laboratories
- Business overview
- Geographic presence
- Product portfolio
- Financial facts
- Relevant news and strategic view
- Sanofi
- Bayer AG
- Becton, Dickinson and Company
- Dexcom, Inc.
- Eli Lilly and Company
- GlaxoSmithKline
- Insulet Corporation
- Medtronic plc
- Novo Nordisk A/S
- Roche Diabetes Care
- Tandem Diabetes Care, Inc.
- Abbott Laboratories
- Conclusion & Recommendations
Frequently asked questions about this report
What is the anticipated CAGR for the type 1 diabetes treatment market?
The type 1 diabetes treatment market is anticipated to expand at a CAGR of 7.8% CAGR from 2023 to 2032.
How big is the type 1 diabetes treatment market?
The type 1 diabetes treatment market was estimated to be US$ 7.02 Billion in 2022.
Which are the companies operating in the global type 1 diabetes treatment industry?
Abbott Laboratories (USA), Sanofi (France), Bayer AG (Germany), Becton, Dickinson and Company (USA), Dexcom, Inc. (USA), Eli Lilly and Company (USA), GlaxoSmithKline (UK), Insulet Corporation (USA), Medtronic plc (Ireland), Novo Nordisk A/S (Denmark), Roche Diabetes Care (Switzerland), Tandem Diabetes Care, Inc. (USA), Ypsomed Holding AG (Switzerland) among others, are the major players in this market.
What are the major driving factors in the type 1 diabetes treatment market?
The global type 1 diabetes market is driven by several factors, including the increasing prevalence of diabetes, growing awareness about diabetes and its management, advancements in insulin delivery devices and growing awareness about the benefits of early diabetes diagnosis and treatment.
Which product type is the largest in the type 1 diabetes treatment market?
The insulin delivery devices segment is the largest segment in the type 1 diabetes market, based on product type. This is due to the growing adoption of insulin pumps and pen injectors, which have improved the quality of life for people with diabetes and made it easier for them to manage their condition.
Why home care is the largest end-user in the type 1 diabetes treatment market?
The largest end-user segment in the market is home care, primarily due to the increasing trend of home-based diabetes management.
Which region will lead the type 1 diabetes treatment market?
North America region will lead the global type 1 diabetes treatment market. The North American market is characterized by strong healthcare infrastructure, a high standard of living, and a large patient pool, making it an attractive market for companies operating in the type 1 diabetes treatment space.